Postdoc Position in Cancer Research UK Manchester Institute, UK

в Cancer Research UK Manchester Institute (посмотреть профиль)
Город Manchester, United Kingdom
Опубликовано 08.06.2023
Категория Мокрая биология

Обязанности

Study the mechanisms governing host-microbiome interactions that permit systemic immune responses to cancer under the influence of host-genetics and diet. The successful candidate will combine in vivo mouse models and samples from cancer patients with the use of flow cytometry, microscopy, microbiota and single-cell gene expression analysis to identify instructive factors of microbiomedependent cancer immunity.

Who are we?

In the Cancer Immunosurveillance group (www.cruk.manchester.ac.uk/Our-Research/Cancer-Immunosurveillance), we combine genetically modified mouse models and tumour engineering to disentangle complex tumour-host interactions that underpin cancer immunity. We have previously shown that immune detection of dying tumour cells can elicit anti-cancer immunity. We have characterised the mechanisms that couple recognition of deadcell- associated signals to CD8+ T cells responses and identified molecules of the host that act as natural barriers of cell death sensing, inhibiting anti-cancer immunity (Giampazolias et al Nature Cell Biology, 2017, Giampazolias et al Cell Cycle, 2018, Giampazolias et al Cell, 2021, Lim KHJ et al JITC, 2022). Interaction of dying cancer cells with the immune system is necessary but not sufficient to elicit cancer immunity due to the requirement of immunological permissive environments dictated by the gut microbiome. However, how the gut-resident microbes are regulated and modulate immune responses to cancer remains unclear. Intriguingly, we recently found that the prevalence of a specific micronutrient and its interaction with host components tune the integration of gut-associated microbial signals to the immune system, acting as determinant of anticancer immunity (Giampazolias* et al under revision, *Corresponding author). Our ultimate vision is to contribute to the basic understanding of cancer immunity and pave the way for therapeutic interventions. Why choose Cancer Research UK Manchester Institute? The Cancer Research UK Manchester Institute is core funded by Cancer Research UK, the largest independent cancer research organisation in the world. In spring 2023 the Institute moved into a £150 million flagship purpose-built biomedical research centre directly attached to The Christie NHS Foundation Trust, in South Manchester. The building is part of the Manchester Cancer Research Centre – a highly successful partnership between 3 powerhouses of innovation, The Christie, Cancer Research UK and The University of Manchester and hosts the largest concentration of scientists, clinicians and operational staff in Europe.Who are we? In the Cancer Immunosurveillance group (www.cruk.manchester.ac.uk/Our-Research/Cancer-Immunosurveillance), we combine genetically modified mouse models and tumour engineering to disentangle complex tumour-host interactions that underpin cancer immunity. We have previously shown that immune detection of dying tumour cells can elicit anti-cancer immunity. We have characterised the mechanisms that couple recognition of deadcell- associated signals to CD8+ T cells responses and identified molecules of the host that act as natural barriers of cell death sensing, inhibiting anti-cancer immunity (Giampazolias et al Nature Cell Biology, 2017, Giampazolias et al Cell Cycle, 2018, Giampazolias et al Cell, 2021, Lim KHJ et al JITC, 2022). Interaction of dying cancer cells with the immune system is necessary but not sufficient to elicit cancer immunity due to the requirement of immunological permissive environments dictated by the gut microbiome. However, how the gut-resident microbes are regulated and modulate immune responses to cancer remains unclear. Intriguingly, we recently found that the prevalence of a specific micronutrient and its interaction with host components tune the integration of gut-associated microbial signals to the immune system, acting as determinant of anticancer immunity (Giampazolias* et al under revision, *Corresponding author). Our ultimate vision is to contribute to the basic understanding of cancer immunity and pave the way for therapeutic interventions. Why choose Cancer Research UK Manchester Institute? The Cancer Research UK Manchester Institute is core funded by Cancer Research UK, the largest independent cancer research organisation in the world. In spring 2023 the Institute moved into a £150 million flagship purpose-built biomedical research centre directly attached to The Christie NHS Foundation Trust, in South Manchester. The building is part of the Manchester Cancer Research Centre – a highly successful partnership between 3 powerhouses of innovation, The Christie, Cancer Research UK and The University of Manchester and hosts the largest concentration of scientists, clinicians and operational staff in Europe.Who are we? In the Cancer Immunosurveillance group (www.cruk.manchester.ac.uk/Our-Research/Cancer-Immunosurveillance), we combine genetically modified mouse models and tumour engineering to disentangle complex tumour-host interactions that underpin cancer immunity. We have previously shown that immune detection of dying tumour cells can elicit anti-cancer immunity. We have characterised the mechanisms that couple recognition of deadcell- associated signals to CD8+ T cells responses and identified molecules of the host that act as natural barriers of cell death sensing, inhibiting anti-cancer immunity (Giampazolias et al Nature Cell Biology, 2017, Giampazolias et al Cell Cycle, 2018, Giampazolias et al Cell, 2021, Lim KHJ et al JITC, 2022). Interaction of dying cancer cells with the immune system is necessary but not sufficient to elicit cancer immunity due to the requirement of immunological permissive environments dictated by the gut microbiome. However, how the gut-resident microbes are regulated and modulate immune responses to cancer remains unclear. Intriguingly, we recently found that the prevalence of a specific micronutrient and its interaction with host components tune the integration of gut-associated microbial signals to the immune system, acting as determinant of anticancer immunity (Giampazolias* et al under revision, *Corresponding author). Our ultimate vision is to contribute to the basic understanding of cancer immunity and pave the way for therapeutic interventions. Why choose Cancer Research UK Manchester Institute? The Cancer Research UK Manchester Institute is core funded by Cancer Research UK, the largest independent cancer research organisation in the world. In spring 2023 the Institute moved into a £150 million flagship purpose-built biomedical research centre directly attached to The Christie NHS Foundation Trust, in South Manchester. The building is part of the Manchester Cancer Research Centre – a highly successful partnership between 3 powerhouses of innovation, The Christie, Cancer Research UK and The University of Manchester and hosts the largest concentration of scientists, clinicians and operational staff in Europe.

Требования

A background in immunology and/or working with cancer models in vivo is required.

Условия

Starting Salary: £32,868 - £42,717 (dependent upon qualifications and experience)
Closing date: 25th June 2023
Duration of Post: Fixed up to 3 years initially with the potential to extend up to a total of 7 years
Link to apply: https://www.cruk.manchester.ac.uk/recruitment/candidate/searchvacancies

Рекомендуемые курсы для этой вакансии: